Phase 3 VALOR Data Further Support Tofersen’s Impact on ALS Disease Progression, Survival Marco Meglio

Published Date: 18 Jan 2026

Published phase 3 data in JAMA Neurology highlighted tofersen's potential to slow ALS progression and improve survival, marking a breakthrough in SOD1-ALS treatment.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

2.

FDA Investigating Blood Cancer Risk With Gene Therapy Skysona

3.

Surviving cancer, still suffering: Survey reveals gaps in follow‑up care

4.

Charles III, King of Kings, is Cancerous.

5.

The Truth About Apple AirPods


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot